ciprofloxacin has been researched along with Breast Neoplasms in 23 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Early-stage breast cancer patients receiving TC chemotherapy were randomised to either ciprofloxacin or G-CSF." | 9.30 | Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC). ( Clemons, M; Fergusson, D; Hilton, J; Hutton, B; Ibrahim, MF; Joy, A; Kehoe, A; Mallick, R; Mazzarello, S; Price-Hiller, J; Sienkiewicz, M; Stober, C; Vandermeer, L; Verma, S; Zhu, X, 2019) |
| " This study was conducted to determine whether oral and intravenous (IV) PTX and Cipro permits increased dose levels of oral busulfan (BU) with a fixed dose of IV cyclophosphamide (CY) in patients with breast cancer receiving autologous or syngeneic hematopoetic cell transplantation." | 9.11 | Dose escalation of busulfan with pentoxifylline and ciprofloxacin in patients with breast cancer undergoing autologous transplants. ( Bensinger, WI; Buckner, CD; Holmberg, L; Lilleby, K; Slattery, JT; Storb, R, 2004) |
| "In a prospective randomized trial, 40 stage IV breast cancer patients undergoing intermediate high-dose chemotherapy (cyclophosphamide, 5-fluorouracil plus epirubicin or methotrexate), received either recombinant human G-CSF (rhG-CSF, group I) or ciprofloxacin and amphotericin B (CAB, group II) for prevention of febrile leucopenia (FL)." | 9.09 | Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B. ( de Vries, EG; Hospers, GA; Mulder, NH; Schröder, CP; Sleijfer, DT; van der Graaf, WT; Willemse, PH, 1999) |
| "This study aimed to investigate the effect of the new ciprofloxacin chalcone [7-(4-(N-substituted carbamoyl methyl) piperazin-1 yl)] on the proliferation, migration, and metastasis of MCF-7 and MDA-MB-231 breast cancer cell lines." | 8.02 | Modulation of Apoptosis and Epithelial-Mesenchymal Transition E-cadherin/TGF-β/Snail/TWIST Pathways by a New Ciprofloxacin Chalcone in Breast Cancer Cells. ( Abuo-Rahma, GEA; Alaaeldin, R; Fathy, M; Zhao, QL, 2021) |
| "We therefore investigated the ability of difloxacin, a quinolone antimicrobial antibiotic, to increase drug cytotoxicity in unselected cultured human neuroblastoma cells." | 7.71 | Reversal of multidrug resistance-associated protein-mediated drug resistance in cultured human neuroblastoma cells by the quinolone antibiotic difloxacin. ( Gilbert, J; Haber, M; Madafiglio, J; Marshall, GM; Norris, MD, 2001) |
| "Patients with stage T2-T4 primary breast cancer were scheduled to receive 6-8 cycles of TAC." | 6.73 | Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. ( Costa, SD; du Bois, A; Eidtmann, H; Eiermann, W; Gerber, B; Grasshoff, ST; Hilfrich, J; Huober, J; Jackisch, C; Kaufmann, M; Kümmel, S; Loibl, S; Mehta, KM; Skacel, T; Vescia, S; von Minckwitz, G, 2008) |
| "Early-stage breast cancer patients receiving TC chemotherapy were randomised to either ciprofloxacin or G-CSF." | 5.30 | Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC). ( Clemons, M; Fergusson, D; Hilton, J; Hutton, B; Ibrahim, MF; Joy, A; Kehoe, A; Mallick, R; Mazzarello, S; Price-Hiller, J; Sienkiewicz, M; Stober, C; Vandermeer, L; Verma, S; Zhu, X, 2019) |
| " This study was conducted to determine whether oral and intravenous (IV) PTX and Cipro permits increased dose levels of oral busulfan (BU) with a fixed dose of IV cyclophosphamide (CY) in patients with breast cancer receiving autologous or syngeneic hematopoetic cell transplantation." | 5.11 | Dose escalation of busulfan with pentoxifylline and ciprofloxacin in patients with breast cancer undergoing autologous transplants. ( Bensinger, WI; Buckner, CD; Holmberg, L; Lilleby, K; Slattery, JT; Storb, R, 2004) |
| "In a prospective randomized trial, 40 stage IV breast cancer patients undergoing intermediate high-dose chemotherapy (cyclophosphamide, 5-fluorouracil plus epirubicin or methotrexate), received either recombinant human G-CSF (rhG-CSF, group I) or ciprofloxacin and amphotericin B (CAB, group II) for prevention of febrile leucopenia (FL)." | 5.09 | Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B. ( de Vries, EG; Hospers, GA; Mulder, NH; Schröder, CP; Sleijfer, DT; van der Graaf, WT; Willemse, PH, 1999) |
| "We studied the effectiveness of prophylactic oral ciprofloxacin and rifampin on fever prevention in patients undergoing autologous bone marrow transplantation (ABMT) for breast cancer." | 5.07 | Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. ( Gilbert, C; Hussein, A; Meisenberg, B; Perfect, J; Peters, WP; Ross, M; Vredenburgh, J, 1994) |
| "This study aimed to investigate the effect of the new ciprofloxacin chalcone [7-(4-(N-substituted carbamoyl methyl) piperazin-1 yl)] on the proliferation, migration, and metastasis of MCF-7 and MDA-MB-231 breast cancer cell lines." | 4.02 | Modulation of Apoptosis and Epithelial-Mesenchymal Transition E-cadherin/TGF-β/Snail/TWIST Pathways by a New Ciprofloxacin Chalcone in Breast Cancer Cells. ( Abuo-Rahma, GEA; Alaaeldin, R; Fathy, M; Zhao, QL, 2021) |
| "Of the 60 consecutive patients who received neoadjuvant chemotherapy as a phase II trial of docetaxel (60 mg/m(2)) and doxorubicin (50 mg/m(2)) for primary breast cancer, 30 low-risk febrile patients received oral ciprofloxacin." | 3.74 | The outpatient management of low-risk febrile patients with neutropenia: risk assessment over the telephone. ( Ando, M; Katsumata, N; Mizuno, T; Mukai, H; Shimizu, C; Watanabe, T, 2007) |
| "We therefore investigated the ability of difloxacin, a quinolone antimicrobial antibiotic, to increase drug cytotoxicity in unselected cultured human neuroblastoma cells." | 3.71 | Reversal of multidrug resistance-associated protein-mediated drug resistance in cultured human neuroblastoma cells by the quinolone antibiotic difloxacin. ( Gilbert, J; Haber, M; Madafiglio, J; Marshall, GM; Norris, MD, 2001) |
| "Patients with stage T2-T4 primary breast cancer were scheduled to receive 6-8 cycles of TAC." | 2.73 | Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. ( Costa, SD; du Bois, A; Eidtmann, H; Eiermann, W; Gerber, B; Grasshoff, ST; Hilfrich, J; Huober, J; Jackisch, C; Kaufmann, M; Kümmel, S; Loibl, S; Mehta, KM; Skacel, T; Vescia, S; von Minckwitz, G, 2008) |
| "Treatment of ADG-2e against metastatic breast cancer cells (MDA-MB-231) suppressed tumor cell migration by multi-directional lamellipodium formation, indicating their anti-metastatic potential." | 1.56 | Antibacterial AZT derivative regulates metastasis of breast cancer cells. ( Bang, JK; Chirumarry, S; Gunasekaran, P; Han, J; Kim, EY; Lee, YH; Ryu, EK; Shin, SY; Soung, NK, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (17.39) | 18.2507 |
| 2000's | 9 (39.13) | 29.6817 |
| 2010's | 7 (30.43) | 24.3611 |
| 2020's | 3 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Trawneh, SA | 2 |
| Zahra, JA | 2 |
| Kamal, MR | 1 |
| El-Abadelah, MM | 2 |
| Zani, F | 2 |
| Incerti, M | 2 |
| Cavazzoni, A | 2 |
| Alfieri, RR | 1 |
| Petronini, PG | 1 |
| Vicini, P | 2 |
| Al-Taweel, SA | 1 |
| Kamal, A | 1 |
| Shaheer Malik, M | 1 |
| Bajee, S | 1 |
| Azeeza, S | 1 |
| Faazil, S | 1 |
| Ramakrishna, S | 1 |
| Naidu, VG | 1 |
| Vishnuwardhan, MV | 1 |
| Chirumarry, S | 1 |
| Soung, NK | 1 |
| Han, J | 1 |
| Kim, EY | 1 |
| Ryu, EK | 1 |
| Lee, YH | 1 |
| Shin, SY | 1 |
| Gunasekaran, P | 1 |
| Bang, JK | 1 |
| Joya, CA | 1 |
| Deegan, C | 1 |
| Gleeson, TD | 1 |
| Alaaeldin, R | 1 |
| Abuo-Rahma, GEA | 1 |
| Zhao, QL | 1 |
| Fathy, M | 1 |
| Clemons, M | 1 |
| Mazzarello, S | 1 |
| Hilton, J | 1 |
| Joy, A | 1 |
| Price-Hiller, J | 1 |
| Zhu, X | 1 |
| Verma, S | 1 |
| Kehoe, A | 1 |
| Ibrahim, MF | 1 |
| Sienkiewicz, M | 1 |
| Stober, C | 1 |
| Vandermeer, L | 1 |
| Hutton, B | 1 |
| Mallick, R | 1 |
| Fergusson, D | 1 |
| Elktaibi, A | 1 |
| Elochi, MR | 1 |
| Sinaa, M | 1 |
| Allaoui, M | 1 |
| Alami, Y | 1 |
| Amrani, M | 1 |
| Sulpher, J | 1 |
| Giguere, P | 1 |
| Hopkins, S | 1 |
| Dent, S | 1 |
| Kitada, N | 1 |
| Nishino, M | 1 |
| Yasuda, J | 1 |
| Morita, S | 1 |
| Fujii, C | 1 |
| Minegaki, T | 1 |
| Kondoh, M | 1 |
| Anami, S | 1 |
| Takara, K | 1 |
| Watari, M | 1 |
| Shi, ZY | 1 |
| Li, YQ | 1 |
| Kang, YH | 1 |
| Hu, GQ | 1 |
| Huang-fu, CS | 1 |
| Deng, JB | 1 |
| Liu, B | 1 |
| Gowda, RV | 1 |
| Stout, R | 1 |
| Smith, RE | 1 |
| Bryant, J | 1 |
| DeCillis, A | 1 |
| Anderson, S | 1 |
| Bensinger, WI | 1 |
| Buckner, CD | 1 |
| Lilleby, K | 1 |
| Holmberg, L | 1 |
| Storb, R | 1 |
| Slattery, JT | 1 |
| Mizuno, T | 1 |
| Katsumata, N | 1 |
| Mukai, H | 1 |
| Shimizu, C | 1 |
| Ando, M | 1 |
| Watanabe, T | 1 |
| von Minckwitz, G | 1 |
| Kümmel, S | 1 |
| du Bois, A | 1 |
| Eiermann, W | 1 |
| Eidtmann, H | 1 |
| Gerber, B | 1 |
| Hilfrich, J | 1 |
| Huober, J | 1 |
| Costa, SD | 1 |
| Jackisch, C | 1 |
| Grasshoff, ST | 1 |
| Vescia, S | 1 |
| Skacel, T | 1 |
| Loibl, S | 1 |
| Mehta, KM | 1 |
| Kaufmann, M | 1 |
| Elwood, ET | 1 |
| Sommerville, DN | 1 |
| Murray, JD | 1 |
| Hsu, PK | 1 |
| Hsu, WH | 1 |
| Eidelman, G | 1 |
| Shapira, Y | 1 |
| Lishner, M | 1 |
| Shalit, I | 1 |
| Kletter, Y | 1 |
| Fabian, I | 1 |
| Gilbert, C | 1 |
| Meisenberg, B | 1 |
| Vredenburgh, J | 1 |
| Ross, M | 1 |
| Hussein, A | 1 |
| Perfect, J | 1 |
| Peters, WP | 1 |
| Bloch, KC | 1 |
| Nadarajah, R | 1 |
| Jacobs, R | 1 |
| Schröder, CP | 1 |
| de Vries, EG | 1 |
| Mulder, NH | 1 |
| Willemse, PH | 1 |
| Sleijfer, DT | 1 |
| Hospers, GA | 1 |
| van der Graaf, WT | 1 |
| Norris, MD | 1 |
| Madafiglio, J | 1 |
| Gilbert, J | 1 |
| Marshall, GM | 1 |
| Haber, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Feasibility of Using an Integrated Consent Model to Compare Two Standard of Care Regimens for Primary Prophylaxis of Taxotere/Cyclophosphamide-Induces Febrile Neutropenia[NCT02173262] | Phase 4 | 142 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| Intermittent Every Other Days of 5 Shot-filgrastim Compared With Single Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide Chemotherapy (Intermittent G-CSF 105)[NCT02685111] | Phase 2 | 22 participants (Actual) | Interventional | 2016-02-29 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ciprofloxacin and Breast Neoplasms
| Article | Year |
|---|---|
Chryseobacterium meningosepticum: an emerging pathogen among immunocompromised adults. Report of 6 cases and literature review.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotics, Antitubercular; Breast Neoplasms; Ciprofloxacin; Dr | 1997 |
7 trials available for ciprofloxacin and Breast Neoplasms
| Article | Year |
|---|---|
Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC).
Topics: Adult; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cip | 2019 |
[Equalization of breast cancer chemotherapy at general hospital( II )-evaluation of safety in FEC and TC regimens].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Ciprofloxa | 2009 |
Dose escalation of busulfan with pentoxifylline and ciprofloxacin in patients with breast cancer undergoing autologous transplants.
Topics: Adult; Anti-Infective Agents; Bone Marrow Transplantation; Breast Neoplasms; Busulfan; Ciprofloxacin | 2004 |
Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ciprofloxacin; Cyclop | 2008 |
Effect of ciprofloxacin on hematologic parameters in breast cancer patients receiving chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Count; Ciprofloxacin; C | 1995 |
Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; B | 1994 |
Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B.
Topics: Adult; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ciprofloxac | 1999 |
15 other studies available for ciprofloxacin and Breast Neoplasms
| Article | Year |
|---|---|
Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell | 2010 |
Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell | 2011 |
Synthesis and biological evaluation of conformationally flexible as well as restricted dimers of monastrol and related dihydropyrimidones.
Topics: Anti-Infective Agents; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Colonic Neoplasms; | 2011 |
Antibacterial AZT derivative regulates metastasis of breast cancer cells.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Breast Neoplasms; Cell Movement; Cell Proliferation; C | 2020 |
Topics: Adult; Anti-Bacterial Agents; Breast Neoplasms; Ciprofloxacin; Debridement; Doxycycline; Female; Hum | 2021 |
Modulation of Apoptosis and Epithelial-Mesenchymal Transition E-cadherin/TGF-β/Snail/TWIST Pathways by a New Ciprofloxacin Chalcone in Breast Cancer Cells.
Topics: Apoptosis; Breast Neoplasms; Cadherins; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; | 2021 |
[Pseudotumoral malakoplakia of the breast].
Topics: Breast Neoplasms; Ciprofloxacin; Female; Humans; Malacoplakia; Middle Aged; Tuberculosis | 2015 |
Impact of an electronic tool in prescribing primary prophylaxis with ciprofloxacin or granulocyte colony-stimulating factor for breast cancer patients receiving TC chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ciprofloxacin; Female | 2016 |
Piperonal ciprofloxacin hydrazone induces growth arrest and apoptosis of human hepatocarcinoma SMMC-7721 cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Hepatocellular; Cell | 2012 |
Pasteurella multocida infection in a post-chemotherapy neutropenic host following cat exposure.
Topics: Aged; Animals; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 2002 |
Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cipr | 2003 |
The outpatient management of low-risk febrile patients with neutropenia: risk assessment over the telephone.
Topics: Adult; Aged; Ambulatory Care; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; | 2007 |
Periorbital necrotizing fasciitis.
Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Breast Neoplasms; | 2007 |
Chest wall mass caused by salmonella enteritidis - a pitfall of PET imaging interpretation.
Topics: Aged; Anti-Infective Agents; Breast Neoplasms; Ceftriaxone; Ciprofloxacin; Female; Fluorodeoxyglucos | 2008 |
Reversal of multidrug resistance-associated protein-mediated drug resistance in cultured human neuroblastoma cells by the quinolone antibiotic difloxacin.
Topics: Adenocarcinoma; Anti-Infective Agents; Antimony Potassium Tartrate; ATP-Binding Cassette Transporter | 2001 |